| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 01/23/2003 | US20030017196 Oligonucleotide inhibitors of bcl-xL |
| 01/23/2003 | US20030017174 Containing herpes simplex virus VP22 polypeptides capable of eliciting a cellular immune response |
| 01/23/2003 | US20030017172 Feline polynucleotide vaccine formula |
| 01/23/2003 | US20030017160 Human checkpoint kinase, hCDS1, compositions and methods |
| 01/23/2003 | US20030017157 Endothelial cell expression patterns |
| 01/23/2003 | US20030017155 Treating a condition characterized by activation of the inflammatory cytokine cascade |
| 01/23/2003 | US20030017153 Determining whether a patient's immune system can be modified through stimulation of thymus function; sex steroids are ablated in the patient, and the resulting production of thymic factors is monitored. |
| 01/23/2003 | US20030017151 Receptor Activator of NF-kappa B antagonists; treatment of medical conditions that require the formation of new bone. |
| 01/23/2003 | US20030017140 Retroviral vector particles have a chimeric envelope protein consisting of an antigen binding site of an antibody or another peptide, fused to the envelope protein the retroviral vector. |
| 01/23/2003 | US20030017139 Regulatory elements for delivery to the liver |
| 01/23/2003 | US20030017137 Vpr-driven dna or rna construct and therapeutic uses thereof |
| 01/23/2003 | CA2821544A1 Use of follistatin for the treatment of pulmonary fibrosis and fibrosis associated with inflammatory bowel disease |
| 01/23/2003 | CA2454135A1 Gpcs as modifiers of the irrtk and p21 pathways and methods of use |
| 01/23/2003 | CA2453928A1 Cell and transgenic animal modelling human antigenic presentation and their uses |
| 01/23/2003 | CA2453566A1 Method and composition for inhibiting heparanase activity |
| 01/23/2003 | CA2453531A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 01/23/2003 | CA2453470A1 Use of follistatin for the treatment of hepatic fibrogenesis |
| 01/23/2003 | CA2453405A1 Pseudotyped adeno-associated viruses and uses thereof |
| 01/23/2003 | CA2453403A1 Methods of inhibiting amyloid toxicity |
| 01/23/2003 | CA2453362A1 Oligonucleotide-containing pharmacological compositions and their use |
| 01/23/2003 | CA2453357A1 Anti-neoplastic viral agents |
| 01/23/2003 | CA2453187A1 Production of transduced hematopoietic progenitor cells |
| 01/23/2003 | CA2453183A1 In vivo production of small interfering rnas that mediate gene silencing |
| 01/23/2003 | CA2453161A1 Lymphatic endothelial cells materials and methods |
| 01/23/2003 | CA2452544A1 Method for treating secondary tissue degeneration associated with central nervous system injury |
| 01/23/2003 | CA2452517A1 Recombinant vsv for the treatment of tumor cells |
| 01/22/2003 | EP1277843A2 Novel human genes and gene expression products related to colon cancer |
| 01/22/2003 | EP1277836A1 Modulation of the IAPs and NAIP for the treatment of proliferative diseases |
| 01/22/2003 | EP1276907A2 Viral vectors for use in monitoring hiv drug resistance |
| 01/22/2003 | EP1276902A2 Methods and materials relating to carcinoembryonic antigen-like (cea-like) polypeptides and polynucleotides |
| 01/22/2003 | EP1276893A1 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 01/22/2003 | EP1276887A2 Protection against environmental toxicity through manipulation of the processing of messenger rna precursors |
| 01/22/2003 | EP1276877A2 Agent for postoperative use after the removal of bone tumours |
| 01/22/2003 | EP1276872A2 A thymus expressed human cytochrome p450 (p450tec) |
| 01/22/2003 | EP1276867A2 Regulation of human latrophilin-like g protein-coupled receptor |
| 01/22/2003 | EP1276863A1 Isolated nucleic acid molecules encoding cancer associated antigens, the antigens per se, and uses thereof |
| 01/22/2003 | EP1276856A1 Albumin fusion proteins |
| 01/22/2003 | EP1276853A1 Pneumovirus ns proteins antagonising the interferon (ifn) response |
| 01/22/2003 | EP1276852A2 Viruses comprising mutated ion channel protein |
| 01/22/2003 | EP1276849A2 Albumin fusion proteins |
| 01/22/2003 | EP1276762A1 Porphyromonas gingivalis recombinant proteins and truncations |
| 01/22/2003 | EP1276760A2 Polyamide nucleic acid derivatives, agents and methods for producing them |
| 01/22/2003 | EP1276750A1 Antisense modulation of zinc finger protein-217 expression |
| 01/22/2003 | EP1276508A2 A particulate complex for administering nucleic acid into a cell |
| 01/22/2003 | EP1276505A1 Mixtures of triblock polyesterpolyethylene glycol copolymers |
| 01/22/2003 | EP1276500A1 Blocking leukocyte emigration and inflammation by interfering with cd99/hec2 |
| 01/22/2003 | EP1276494A1 A memory enhancing protein |
| 01/22/2003 | EP1161142A4 Methods for culturing fluid-filled sensory organs |
| 01/22/2003 | EP0963207A4 Il-12 gene therapy of tumors |
| 01/22/2003 | EP0853660B1 Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicine |
| 01/22/2003 | EP0850070B1 Use of cyclodextrins to modulate gene expression with reduced immunostimulatory response |
| 01/21/2003 | US6509446 Recombinant genetic information (DNA or RNA), consisting a Chicken Anemia Virus (CAV)-specific nucleotide sequence, useful for diagonestics, vaccination or protein production |
| 01/21/2003 | US6509321 Treatment of Kaposi's sarcoma with IL-12 |
| 01/21/2003 | US6509162 Methods for selectively modulating survivin apoptosis pathways |
| 01/21/2003 | US6509151 DNA molecule encoding a Mycobacterium protein and conferring on Mycobacterium tuberculosis an ability to enter mammalian cells and to survive within macrophages |
| 01/21/2003 | US6509020 Replication-competent herpes simplex virus |
| 01/21/2003 | US6509016 Delaying recurrence of ganglioside 2 associated tumors; antibody comprising the light and heavy chain variable region sequences contained in seq id no: 2 and 4 |
| 01/21/2003 | CA2204253C Methods and devices for immunizing a host through administration of naked polynucleotides which encode antigenic peptides |
| 01/21/2003 | CA2098720C Cellular composition for the treatment of human or animal organisms |
| 01/18/2003 | CA2352702A1 Novel human proton gated ion channel |
| 01/17/2003 | CA2352439A1 Engineering oncolytic viruses |
| 01/16/2003 | WO2003004704A2 Method of selecting dna sequence with transcription modulating activity using a vector comprising an element with a gene transcription repressing activity |
| 01/16/2003 | WO2003004685A2 Soluble steroidal peptides for nucleic acid delivery |
| 01/16/2003 | WO2003004683A2 Nucleic acids encoding recombinant 56 and 82 kda antigens from gametocytes of eimeria maxima and their uses |
| 01/16/2003 | WO2003004661A2 Adenovital vectors with cell type specificity for mesenchymal cells |
| 01/16/2003 | WO2003004660A1 Methods of administering vectors to synaptically connected neurons |
| 01/16/2003 | WO2003004657A1 Polynucleotides encoding antigenic hiv type b and/or type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | WO2003004655A2 Use of the cd24 marker gene for the selection of keratinocyte stem cells transformed by exogenous sequences |
| 01/16/2003 | WO2003004637A1 Utilization of histamine receptor h3 gene participating in body weight or food intake control |
| 01/16/2003 | WO2003004620A2 Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| 01/16/2003 | WO2003004600A2 Improvement of viral uptake into cells and tissues |
| 01/16/2003 | WO2003004533A1 Immunological binding molecules inhibiting the syncytial fusion of trophoblast cells |
| 01/16/2003 | WO2003004526A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or resistance to viruses and their use as medicines |
| 01/16/2003 | WO2003004520A2 Mycobacterial antigens expressed during latency |
| 01/16/2003 | WO2003004517A2 Peyers's patch and/or m-celle targeting ligands |
| 01/16/2003 | WO2003004088A2 Method of administration of a gene of interest to the heart and vasculature |
| 01/16/2003 | WO2003004067A1 Methods and compositions for the treatment and diagnosis of body weight disorders |
| 01/16/2003 | WO2003004066A1 Gene therapeutics |
| 01/16/2003 | WO2003004065A1 Method of transporting physiological polymer using protein having rxp repeated sequence |
| 01/16/2003 | WO2003004064A2 Products for treating ovarian cancers and for preventing relapses |
| 01/16/2003 | WO2003004063A1 Genetically engineered therapy method for treating gnrh receptor-positive carcinoma by gnrh-induced tumor cell-specific activation of a therapeutic gene, corresponding nucleic acid constructs and vectors |
| 01/16/2003 | WO2003004057A1 Ephrin and eph receptor mediated immune modulation |
| 01/16/2003 | WO2003004056A1 Method for treating multiple myeloma |
| 01/16/2003 | WO2003004037A1 Xenogenic oligoor/and polyribonucleotides as agents for the treatment of malignant tumours |
| 01/16/2003 | WO2003003941A2 One dose vaccination with mycoplasma hyopneumoniae |
| 01/16/2003 | WO2002094194A3 Compositions and methods for inhibiting metastasis |
| 01/16/2003 | WO2002077026A3 Gene involved in v(d)j recombination and/or dna repair |
| 01/16/2003 | WO2002077023A3 A new essential downstream component of the wingless signalling pathway |
| 01/16/2003 | WO2002053701A3 Epididymal lipocalin gene and uses thereof |
| 01/16/2003 | WO2002046223A3 Compositions and methods related to the minn1 tumor suppressor gene and protein |
| 01/16/2003 | WO2002040540A3 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor |
| 01/16/2003 | WO2002039955A3 Biodegradable mixed polymeric micelles for drug delivery |
| 01/16/2003 | WO2002031144A3 Identification of cytotoxic activity from the ink of aplysia punctata |
| 01/16/2003 | WO2002031109A3 Intracellular delivery of biological effectors by novel transporter peptide sequences |
| 01/16/2003 | WO2002029026A3 Human proteases and polynucleotides encoding the same |
| 01/16/2003 | WO2002022080A8 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications |
| 01/16/2003 | WO2002020813A3 Recombinant endothelial cell growth inhibitors derived from a mammalian plasminogen |
| 01/16/2003 | WO2002020047A3 Chlamydial peptides and their mimics in demyelinating disease |
| 01/16/2003 | WO2002018609A3 Methods for stable transduction of cells with viral vectors |
| 01/16/2003 | WO2002014352A3 Therapeutic compounds for ovarian cancer |